Jon M. Davison, MD
Associate Professor of Pathology


Dr. Davison is a member of the Division of Anatomic Pathology. He is also a member of the Gastrointestinal Pathology Center of Excellence.

Office Location:
UPMC Presbyterian, Suite A610.1
200 Lothrop Street
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-6125
Fax: 412-647-6251
Email: davisonjm@upmc.edu

Education

  • BA - University of Notre Dame, 1990
  • MD - Pritzker School of Medicine, 2002
  • Residency - Anatomic Pathology, Johns Hopkins Department of Pathology, 2005
  • Fellowship - Gastrointestinal Pathology, Johns Hopkins Department of Pathology, 2006

Clinical Expertise

My clinical expertise is in gastrointestinal pathology, including pathology of the pancreas. I have a special interest in Barrett's esophagus and esophageal neoplasia.

Research Interests

My main academic research interests focus on morphologic and molecular characterization of esophageal adenocarcinoma and Barrett's associated neoplasia with a view towards improving diagnosis and treatment.

Specialties

Anatomic Pathology and Gastrointestinal Pathology

Selected Publications

View Dr. Davison's publications on PubMed

  • Singhi AD, Foxwell TJ, Nason K, Cressman KL, McGrath KM, Sun W, Bahary N, Zeh HJ, Levy RM, Luketich JD, Davison JM. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol. 2015 Apr;39(4):487-95.
  • Singhi AD, Seethala RR, Nason K, Foxwell TJ, Roche RL, McGrath KM, Levy RM, Luketich JD, Davison JM. Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases. Hum Pathol. 2015 Mar;46(3):366-75. doi: 10.1016/j.humpath.2014.11.021. Epub 2014 Dec 17.
  • Regueiro MD, Greer JB, Binion DG, Schraut WH, Goyal A, Keljo DJ, Cross RK, Williams ED, Herfarth HH, Siegel CA, Oikonomou I, Brand MH, Hartman DJ, Tublin ME, Davis PL, Baidoo L, Szigethy E, Watson AR; IBD LIVE Physician Group. The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis. 2014 Oct;20(10):1687-95.
  • Zaidi AH, Gopalakrishnan V, Kasi PM, Zeng X, Malhotra U, Balasubramanian J, Visweswaran S, Sun M, Flint MS, Davison JM, Hood BL, Conrads TP, Bergman JJ, Bigbee WL, Jobe BA. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer. 2014 Dec 15;120(24):3902-13. doi: 10.1002/cncr.28963. Epub 2014 Aug 5.
  • Singhi AD, Davison JM, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, Zureikat AH, Zeh HJ, Ramalingam L, Mantha G, Nikiforova M, Bartlett DL, Pai RK. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Hum Pathol. 2014 Aug;45(8):1737-43. doi: 10.1016/j.humpath.2014.04.018. Epub 2014 May 8.
  • Landau MS, Hastings SM, Foxwell TJ, Luketich JD, Nason KS, Davison JM. Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma. Mod Pathol. 2014 Dec;27(12):1578-89. doi: 10.1038/moadpthol.2014.66. Epub 2014 Apr 25.
  • Davison JM, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, Zureikat AH, Zeh HJ, Ramalingam L, Zhu B, Nikiforova M, Bartlett DL, Pai RK. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014 Nov;27(11):1521-39. doi: 10.1038/modpathol.2014.37. Epub 2014 Mar 14.